<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03179345</url>
  </required_header>
  <id_info>
    <org_study_id>GRAL-PX-8401</org_study_id>
    <nct_id>NCT03179345</nct_id>
  </id_info>
  <brief_title>Simulated Driving Performance, Daytime Sedation and Cognition in Healthy Volunteers Taking Gralise, Neurontin or Lyrica</brief_title>
  <official_title>A Phase 4, Double-Blind, Placebo-Controlled, Crossover Study Comparing Simulated Driving Performance, Daytime Sedation, and Cognition in Healthy Volunteers Taking Therapeutic Doses of Gralise®, Neurontin®, or Lyrica®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Depomed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Depomed</source>
  <brief_summary>
    <textblock>
      Phase 4, double-blind, placebo-controlled, four treatment, four sequence crossover study
      comparing simulated driving performance, daytime sedation and cognition in healthy volunteers
      administered therapeutic doses of Gralise® (Treatment A), Neurontin® (Treatment B), Lyrica®
      (Treatment C) and placebo (Treatment D). All doses were administered under fed conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2015</start_date>
  <completion_date type="Actual">November 20, 2015</completion_date>
  <primary_completion_date type="Actual">November 20, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the &quot;Standard Deviation of the Lateral Position&quot; (SDLP) Measured on the Driving Simulator Between Gralise® and Neurontin®</measure>
    <time_frame>Baseline and Hour 3 on Day 3</time_frame>
    <description>SDLP (feet): This is a measurement of change from maintaining the normal driving position in the lane over time and / or distance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the &quot;Standard Deviation of the Lateral Position&quot; (SDLP) Measured on the Driving Simulator Between Gralise® and Lyrica®</measure>
    <time_frame>Baseline and Hour 3 on Day 3</time_frame>
    <description>SDLP (feet): This is a measurement of change from maintaining the normal driving position in the lane over time and / or distance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Detection Task (DET)</measure>
    <time_frame>Baseline and Hour 3 on Day 3</time_frame>
    <description>Cogstate - Detection Task (DET) is a simple reaction time test of Psychomotor Function. Higher change from baseline means better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Groton Maze Learning Test (GMLT).</measure>
    <time_frame>Baseline and Hour 3 on Day 3</time_frame>
    <description>Cogstate - The Groton Maze Learning test is a measure Executive Function. Total number of errors made while attempting to learn the same hidden pathway across the consecutive learning trials performed at a single assessment. Lower score means better performance. Higher change from baseline means better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Identification Task (IDN).</measure>
    <time_frame>Baseline and Hour 3 on Day 3</time_frame>
    <description>Cogstate - Identification Task (IDN) assesses Attention. Score is speed of performance (mean of the log10 transformed reaction times for correct responses). Lower score (quicker speed) is better performance. Higher change from baseline means better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - International Shopping List Test (ISL)</measure>
    <time_frame>Baseline and Hour 3 on Day 3</time_frame>
    <description>Cogstate - International Shopping List (ISL) test is a measure of verbal learning and uses a well-validated list-learning paradigm. Total number of correct responses remembering the word list on three consecutive trials at a single assessment. Higher score is better performance. Higher change from baseline means better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - One Card Learning (OCLT).</measure>
    <time_frame>Baseline and Hour 3 on Day 3</time_frame>
    <description>Cogstate - The One Card Learning Test (OCLT) is a measure of visual learning and uses a well-validated pattern separation paradigm with playing card stimuli. Higher Score is better performance. Higher change from baseline means better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Sedation Evaluation - Karolinska Sleepiness Scale (KSS).</measure>
    <time_frame>Baseline and Hour 3 on Day 3</time_frame>
    <description>Scale: 1-9, 1=extremely alert, 9 = very sleepy, great effort to keep awake, fighting sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Sedation Evaluation - Portland Neurotoxicity Scale (PNS).</measure>
    <time_frame>Baseline and Hour 3 on Day 3</time_frame>
    <description>Portland Neurotoxicity Scale (PNS) comprises 15 questions measured on a 10-point scale. [1=No problem, 2, 3, 4, 5=Often a problem, 6, 7, 8, 9, 10=Severe problem] in 16 categories. Each question was analyzed and is presented in the same way as the primary endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Between Gralise® and Neurontin® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS).</measure>
    <time_frame>Baseline and Hour 3 on Day 3</time_frame>
    <description>Miles per Hour (mph)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Between Gralise® and Lyrica® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS).</measure>
    <time_frame>Baseline and Hour 3 on Day 3</time_frame>
    <description>Miles per Hour (mph)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare the Relative Safety and Tolerability of Gralise®, Neurontin®, and Lyrica®.</measure>
    <time_frame>Screening to 1 week after Period 4 discharge</time_frame>
    <description>Number of subjects with Treatment-Emergent Adverse Events (TEAE)
Number of subjects with Serious Adverse Event (SAE)
Number of subjects discontinued due to Adverse Event (AE)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Gralise® (gabapentin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gralise® 3 x 600 mg tablets (1800 mg total dose) administered once daily at 7:00 pm on Day 1 and Day 2 with one placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®. At other dosing times, treatment consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neurontin® (gabapentin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neurontin® 1 x 600 mg film-coated tablet administered 3 times daily at 7:00 pm on Day 1, at 8:00 am, 2:00 pm and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Neurontin® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lyrica® (pregabalin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lyrica® 1 x 150 mg capsule administered 2 times daily at 7:00 pm on Day 1, at 8:00 am and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Lyrica® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (sugar pill)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <arm_group_label>Gralise® (gabapentin)</arm_group_label>
    <arm_group_label>Neurontin® (gabapentin)</arm_group_label>
    <other_name>Gralise®, Neurontin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <arm_group_label>Lyrica® (pregabalin)</arm_group_label>
    <other_name>Lyrica®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo (sugar pill)</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 40 and 80 years of age, inclusive.

          -  Body weight &gt; 50 kg and BMI between 18 and 32 kg/m2, inclusive.

          -  Able to give informed consent.

          -  Licensed, experienced driver who had driven at least 3 times a week for the past 3
             years and had visual acuity adequate for driving, as assessed by the investigator or
             designee.

          -  Able to complete a 1 hour simulated driving test and demonstrate satisfactory driving
             skills, as determined by the investigator or designee.

          -  Karolinska Sleep Scale (KSS) score of &lt;=5.

          -  Other criteria apply.

        Exclusion Criteria:

          -  Known history of allergic reaction, hypersensitivity or clinically significant
             intolerance to gabapentin, pregabalin or any pharmaceutical materials, or any of the
             ingredients in the protocol-specified meals.

          -  Pregnant or lactating or considered at risk of pregnancy.

          -  Any medical condition or any laboratory abnormality or ECG abnormality that would, in
             the opinion of the investigator, contraindicate study participation.

          -  Impaired liver function (e.g., alanine aminotransferase [ALT] ≥2 times the upper limit
             of normal [ULN] or bilirubin ≥2 times ULN), known active hepatic disease (e.g.,
             hepatitis), or evidence of clinically significant liver disease or other condition
             affecting the liver that may suggest the potential for an increased susceptibility to
             hepatic toxicity with oral gabapentin or pregabalin exposure.

          -  Any history of renal disease that, in the opinion of the investigator, would
             contraindicate study participation; or subject had significantly impaired renal
             function as evidenced by an estimated GFR of ≤ 80 ml/min/1.73m2.

          -  History or evidence of a sleep disorder, including sleep apnea (obstructive, central
             or mixed), narcolepsy or primary insomnia.

          -  Other criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Head of R&amp;D</last_name>
    <role>Study Director</role>
    <affiliation>Depomed</affiliation>
  </overall_official>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 5, 2017</study_first_submitted>
  <study_first_submitted_qc>June 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <results_first_submitted>January 16, 2018</results_first_submitted>
  <results_first_submitted_qc>April 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 13, 2020</results_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Volunteer</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 32 healthy subjects enrolled in this crossover study. Each subject was randomly assigned to 1 out of 4 treatment sequences.
Abbreviations:
Gral = Gralise®; Neur = Neurontin®; Lyr = Lyrica®; Plbo = Placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gral First, Then Neur, Lyr, and Plbo</title>
          <description>Gralise® (gabapentin) 3 x 600 mg tablets (1800 mg total): Dosed once daily in the evening on Day 1 and Day 2.
Neurontin® (gabapentin) 1 x 600 mg film-coated tablet: Dosed 3 times daily starting in the evening on Day 1, in the morning, afternoon, and evening on Day 2, and in the morning on Day 3.
Lyrica® (pregabalin) 1 x 150 mg capsule: Dosed 2 times daily starting in the evening on Day 1, in the morning and evening on Day 2, and in the morning on Day 3.
Placebo (sugar pill): Three (3) placebo tablets matching the appearance of Gralise® &amp; 1 placebo capsule matching the over-encapsulation of doses of Neurontin® &amp; Lyrica®.
All treatments were administered following a meal.
Each treatment period was separated by a 7-day washout interval.</description>
        </group>
        <group group_id="P2">
          <title>Neur First, Then Plbo, Gral, and Lyr</title>
          <description>Neurontin® (gabapentin) 1 x 600 mg film-coated tablet: Dosed 3 times daily starting in the evening on Day 1, in the morning, afternoon, and evening on Day 2, and in the morning on Day 3.
Placebo (sugar pill): Three (3) placebo tablets matching the appearance of Gralise® &amp; 1 placebo capsule matching the over-encapsulation of doses of Neurontin® &amp; Lyrica®.
Gralise® (gabapentin) 3 x 600 mg tablets (1800 mg total): Dosed once daily in the evening on Day 1 and Day 2.
Lyrica® (pregabalin) 1 x 150 mg capsule: Dosed 2 times daily starting in the evening on Day 1, in the morning and evening on Day 2, and in the morning on Day 3.
All treatments were administered following a meal.
Each treatment period was separated by a 7-day washout interval.</description>
        </group>
        <group group_id="P3">
          <title>Lyr First, Then Gral, Plbo, and Neur</title>
          <description>Lyrica® (pregabalin) 1 x 150 mg capsule: Dosed 2 times daily starting in the evening on Day 1, in the morning and evening on Day 2, and in the morning on Day 3.
Gralise® (gabapentin) 3 x 600 mg tablets (1800 mg total): Dosed once daily in the evening on Day 1 and Day 2.
Placebo (sugar pill): Three (3) placebo tablets matching the appearance of Gralise® &amp; 1 placebo capsule matching the over-encapsulation of doses of Neurontin® &amp; Lyrica®.
Neurontin® (gabapentin) 1 x 600 mg film-coated tablet: Dosed 3 times daily starting in the evening on Day 1, in the morning, afternoon, and evening on Day 2, and in the morning on Day 3.
All treatments were administered following a meal.
Each treatment period was separated by a 7-day washout interval.</description>
        </group>
        <group group_id="P4">
          <title>Plbo First, Then Lyr, Neur, and Gral</title>
          <description>Placebo (sugar pill): Three (3) placebo tablets matching the appearance of Gralise® &amp; 1 placebo capsule matching the over-encapsulation of doses of Neurontin® &amp; Lyrica®.
Lyrica® (pregabalin) 1 x 150 mg capsule: Dosed 2 times daily starting in the evening on Day 1, in the morning and evening on Day 2, and in the morning on Day 3.
Neurontin® (gabapentin) 1 x 600 mg film-coated tablet: Dosed 3 times daily starting in the evening on Day 1, in the morning, afternoon, and evening on Day 2, and in the morning on Day 3.
Gralise® (gabapentin) 3 x 600 mg tablets (1800 mg total): Dosed once daily in the evening on Day 1 and Day 2.
All treatments were administered following a meal.
Each treatment period was separated by a 7-day washout interval.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Gralise®</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Neurontin®</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Lyrica®</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Placebo</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gral First, Then Neur, Lyr, and Plbo</title>
          <description>Gralise® (gabapentin) 3 x 600 mg tablets (1800 mg total): Dosed once daily in the evening on Day 1 and Day 2.
Neurontin® (gabapentin) 1 x 600 mg film-coated tablet: Dosed 3 times daily starting in the evening on Day 1, in the morning, afternoon, and evening on Day 2, and in the morning on Day 3.
Lyrica® (pregabalin) 1 x 150 mg capsule: Dosed 2 times daily starting in the evening on Day 1, in the morning and evening on Day 2, and in the morning on Day 3.
Placebo (sugar pill): Three (3) placebo tablets matching the appearance of Gralise® &amp; 1 placebo capsule matching the over-encapsulation of doses of Neurontin® &amp; Lyrica®.
All treatments were administered following a meal.
Each treatment period was separated by a 7-day washout interval.</description>
        </group>
        <group group_id="B2">
          <title>Neur First, Then Plbo, Gral, and Lyr</title>
          <description>Neurontin® (gabapentin) 1 x 600 mg film-coated tablet: Dosed 3 times daily starting in the evening on Day 1, in the morning, afternoon, and evening on Day 2, and in the morning on Day 3.
Placebo (sugar pill): Three (3) placebo tablets matching the appearance of Gralise® &amp; 1 placebo capsule matching the over-encapsulation of doses of Neurontin® &amp; Lyrica®.
Gralise® (gabapentin) 3 x 600 mg tablets (1800 mg total): Dosed once daily in the evening on Day 1 and Day 2.
Lyrica® (pregabalin) 1 x 150 mg capsule: Dosed 2 times daily starting in the evening on Day 1, in the morning and evening on Day 2, and in the morning on Day 3.
All treatments were administered following a meal.
Each treatment period was separated by a 7-day washout interval.</description>
        </group>
        <group group_id="B3">
          <title>Lyr First, Then Gral, Plbo, and Neur</title>
          <description>Lyrica® (pregabalin) 1 x 150 mg capsule: Dosed 2 times daily starting in the evening on Day 1, in the morning and evening on Day 2, and in the morning on Day 3.
Gralise® (gabapentin) 3 x 600 mg tablets (1800 mg total): Dosed once daily in the evening on Day 1 and Day 2.
Placebo (sugar pill): Three (3) placebo tablets matching the appearance of Gralise® &amp; 1 placebo capsule matching the over-encapsulation of doses of Neurontin® &amp; Lyrica®.
Neurontin® (gabapentin) 1 x 600 mg film-coated tablet: Dosed 3 times daily starting in the evening on Day 1, in the morning, afternoon, and evening on Day 2, and in the morning on Day 3.
All treatments were administered following a meal.
Each treatment period was separated by a 7-day washout interval.</description>
        </group>
        <group group_id="B4">
          <title>Plbo First, Then Lyr, Neur, and Gral</title>
          <description>Placebo (sugar pill): Three (3) placebo tablets matching the appearance of Gralise® &amp; 1 placebo capsule matching the over-encapsulation of doses of Neurontin® &amp; Lyrica®.
Lyrica® (pregabalin) 1 x 150 mg capsule: Dosed 2 times daily starting in the evening on Day 1, in the morning and evening on Day 2, and in the morning on Day 3.
Neurontin® (gabapentin) 1 x 600 mg film-coated tablet: Dosed 3 times daily starting in the evening on Day 1, in the morning, afternoon, and evening on Day 2, and in the morning on Day 3.
Gralise® (gabapentin) 3 x 600 mg tablets (1800 mg total): Dosed once daily in the evening on Day 1 and Day 2.
All treatments were administered following a meal.
Each treatment period was separated by a 7-day washout interval.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.0" spread="5.32"/>
                    <measurement group_id="B2" value="47.6" spread="5.29"/>
                    <measurement group_id="B3" value="51.0" spread="9.35"/>
                    <measurement group_id="B4" value="46.8" spread="4.06"/>
                    <measurement group_id="B5" value="48.6" spread="6.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the &quot;Standard Deviation of the Lateral Position&quot; (SDLP) Measured on the Driving Simulator Between Gralise® and Neurontin®</title>
        <description>SDLP (feet): This is a measurement of change from maintaining the normal driving position in the lane over time and / or distance.</description>
        <time_frame>Baseline and Hour 3 on Day 3</time_frame>
        <population>The above is the only Primary Outcome Measure (comparing the SDLP between Gralise® and Neurontin®).</population>
        <group_list>
          <group group_id="O1">
            <title>Gralise® (Gabapentin)</title>
            <description>Gralise® (gabapentin) 3 x 600 mg tablets (1800 mg total): Dosed once daily in the evening on Day 1 and Day 2.</description>
          </group>
          <group group_id="O2">
            <title>Neurontin® (Gabapentin)</title>
            <description>Neurontin® (gabapentin) 1 x 600 mg film-coated tablet: Dosed 3 times daily starting in the evening on Day 1, in the morning, afternoon, and evening on Day 2, and in the morning on Day 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®: Dosed 3 times daily starting in the evening on Day 1, in the morning, afternoon, and evening on Day 2, and in the morning on Day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the &quot;Standard Deviation of the Lateral Position&quot; (SDLP) Measured on the Driving Simulator Between Gralise® and Neurontin®</title>
          <description>SDLP (feet): This is a measurement of change from maintaining the normal driving position in the lane over time and / or distance.</description>
          <population>The above is the only Primary Outcome Measure (comparing the SDLP between Gralise® and Neurontin®).</population>
          <units>feet</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.255" spread="0.0781"/>
                    <measurement group_id="O2" value="0.395" spread="0.0763"/>
                    <measurement group_id="O3" value="0.135" spread="0.0770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0275</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within Sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.266</ci_lower_limit>
            <ci_upper_limit>-0.016</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0611</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.120</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.006</ci_lower_limit>
            <ci_upper_limit>0.245</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the &quot;Standard Deviation of the Lateral Position&quot; (SDLP) Measured on the Driving Simulator Between Gralise® and Lyrica®</title>
        <description>SDLP (feet): This is a measurement of change from maintaining the normal driving position in the lane over time and / or distance.</description>
        <time_frame>Baseline and Hour 3 on Day 3</time_frame>
        <population>The above is a Secondary Outcome Measure (comparing the SDLP between Gralise® and Lyrica®).</population>
        <group_list>
          <group group_id="O1">
            <title>Gralise® (Gabapentin)</title>
            <description>Gralise® (gabapentin) 3 x 600 mg tablets (1800 mg total): Dosed once daily in the evening on Day 1 and Day 2.</description>
          </group>
          <group group_id="O2">
            <title>Lyrica® (Pregabalin)</title>
            <description>Lyrica® (pregabalin) 1 x 150 mg capsule: Dosed 2 times daily starting in the evening on Day 1, in the morning and evening on Day 2, and in the morning on Day 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®: Dosed 3 times daily starting in the evening on Day 1, in the morning, afternoon, and evening on Day 2, and in the morning on Day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the &quot;Standard Deviation of the Lateral Position&quot; (SDLP) Measured on the Driving Simulator Between Gralise® and Lyrica®</title>
          <description>SDLP (feet): This is a measurement of change from maintaining the normal driving position in the lane over time and / or distance.</description>
          <population>The above is a Secondary Outcome Measure (comparing the SDLP between Gralise® and Lyrica®).</population>
          <units>feet</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.255" spread="0.0781"/>
                    <measurement group_id="O2" value="0.356" spread="0.0770"/>
                    <measurement group_id="O3" value="0.135" spread="0.0770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1103</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.102</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.227</ci_lower_limit>
            <ci_upper_limit>0.024</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0611</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.120</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.006</ci_lower_limit>
            <ci_upper_limit>0.245</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Detection Task (DET)</title>
        <description>Cogstate - Detection Task (DET) is a simple reaction time test of Psychomotor Function. Higher change from baseline means better performance.</description>
        <time_frame>Baseline and Hour 3 on Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gralise® (Gabapentin)</title>
            <description>Gralise® 3 x 600 mg tablets (1800 mg total dose) administered once daily at 7:00 pm on Day 1 and Day 2 with one placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®. At other dosing times, treatment consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule.
Gabapentin</description>
          </group>
          <group group_id="O2">
            <title>Neurontin® (Gabapentin)</title>
            <description>Neurontin® 1 x 600 mg film-coated tablet administered 3 times daily at 7:00 pm on Day 1, at 8:00 am, 2:00 pm and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Neurontin® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
Gabapentin</description>
          </group>
          <group group_id="O3">
            <title>Lyrica® (Pregabalin)</title>
            <description>Lyrica® 1 x 150 mg capsule administered 2 times daily at 7:00 pm on Day 1, at 8:00 am and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Lyrica® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
Pregabalin</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Sugar Pill)</title>
            <description>Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Detection Task (DET)</title>
          <description>Cogstate - Detection Task (DET) is a simple reaction time test of Psychomotor Function. Higher change from baseline means better performance.</description>
          <units>msec</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.013"/>
                    <measurement group_id="O2" value="0.00" spread="0.012"/>
                    <measurement group_id="O3" value="-0.01" spread="0.012"/>
                    <measurement group_id="O4" value="-0.00" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9946</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1673</p_value>
            <method>ANCOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0125</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6208</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0125</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Groton Maze Learning Test (GMLT).</title>
        <description>Cogstate - The Groton Maze Learning test is a measure Executive Function. Total number of errors made while attempting to learn the same hidden pathway across the consecutive learning trials performed at a single assessment. Lower score means better performance. Higher change from baseline means better performance.</description>
        <time_frame>Baseline and Hour 3 on Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gralise® (Gabapentin)</title>
            <description>Gralise® 3 x 600 mg tablets (1800 mg total dose) administered once daily at 7:00 pm on Day 1 and Day 2 with one placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®. At other dosing times, treatment consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule.
Gabapentin</description>
          </group>
          <group group_id="O2">
            <title>Neurontin® (Gabapentin)</title>
            <description>Neurontin® 1 x 600 mg film-coated tablet administered 3 times daily at 7:00 pm on Day 1, at 8:00 am, 2:00 pm and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Neurontin® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
Gabapentin</description>
          </group>
          <group group_id="O3">
            <title>Lyrica® (Pregabalin)</title>
            <description>Lyrica® 1 x 150 mg capsule administered 2 times daily at 7:00 pm on Day 1, at 8:00 am and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Lyrica® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
Pregabalin</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Sugar Pill)</title>
            <description>Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Groton Maze Learning Test (GMLT).</title>
          <description>Cogstate - The Groton Maze Learning test is a measure Executive Function. Total number of errors made while attempting to learn the same hidden pathway across the consecutive learning trials performed at a single assessment. Lower score means better performance. Higher change from baseline means better performance.</description>
          <units>Number of errors on test</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="2.484"/>
                    <measurement group_id="O2" value="-0.01" spread="2.385"/>
                    <measurement group_id="O3" value="-0.64" spread="2.419"/>
                    <measurement group_id="O4" value="3.32" spread="2.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8799</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.60</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.59</ci_lower_limit>
            <ci_upper_limit>4.80</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9277</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.97</ci_lower_limit>
            <ci_upper_limit>5.45</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1587</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.94</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Identification Task (IDN).</title>
        <description>Cogstate - Identification Task (IDN) assesses Attention. Score is speed of performance (mean of the log10 transformed reaction times for correct responses). Lower score (quicker speed) is better performance. Higher change from baseline means better performance.</description>
        <time_frame>Baseline and Hour 3 on Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gralise® (Gabapentin)</title>
            <description>Gralise® 3 x 600 mg tablets (1800 mg total dose) administered once daily at 7:00 pm on Day 1 and Day 2 with one placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®. At other dosing times, treatment consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule.
Gabapentin</description>
          </group>
          <group group_id="O2">
            <title>Neurontin® (Gabapentin)</title>
            <description>Neurontin® 1 x 600 mg film-coated tablet administered 3 times daily at 7:00 pm on Day 1, at 8:00 am, 2:00 pm and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Neurontin® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
Gabapentin</description>
          </group>
          <group group_id="O3">
            <title>Lyrica® (Pregabalin)</title>
            <description>Lyrica® 1 x 150 mg capsule administered 2 times daily at 7:00 pm on Day 1, at 8:00 am and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Lyrica® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
Pregabalin</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Sugar Pill)</title>
            <description>Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - Identification Task (IDN).</title>
          <description>Cogstate - Identification Task (IDN) assesses Attention. Score is speed of performance (mean of the log10 transformed reaction times for correct responses). Lower score (quicker speed) is better performance. Higher change from baseline means better performance.</description>
          <units>Score on Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.000"/>
                    <measurement group_id="O2" value="0.00" spread="0.000"/>
                    <measurement group_id="O3" value="-0.00" spread="0.000"/>
                    <measurement group_id="O4" value="0.01" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7111</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0125</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9048</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3262</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.03</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - International Shopping List Test (ISL)</title>
        <description>Cogstate - International Shopping List (ISL) test is a measure of verbal learning and uses a well-validated list-learning paradigm. Total number of correct responses remembering the word list on three consecutive trials at a single assessment. Higher score is better performance. Higher change from baseline means better performance.</description>
        <time_frame>Baseline and Hour 3 on Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gralise® (Gabapentin)</title>
            <description>Gralise® 3 x 600 mg tablets (1800 mg total dose) administered once daily at 7:00 pm on Day 1 and Day 2 with one placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®. At other dosing times, treatment consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule.
Gabapentin</description>
          </group>
          <group group_id="O2">
            <title>Neurontin® (Gabapentin)</title>
            <description>Neurontin® 1 x 600 mg film-coated tablet administered 3 times daily at 7:00 pm on Day 1, at 8:00 am, 2:00 pm and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Neurontin® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
Gabapentin</description>
          </group>
          <group group_id="O3">
            <title>Lyrica® (Pregabalin)</title>
            <description>Lyrica® 1 x 150 mg capsule administered 2 times daily at 7:00 pm on Day 1, at 8:00 am and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Lyrica® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
Pregabalin</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Sugar Pill)</title>
            <description>Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - International Shopping List Test (ISL)</title>
          <description>Cogstate - International Shopping List (ISL) test is a measure of verbal learning and uses a well-validated list-learning paradigm. Total number of correct responses remembering the word list on three consecutive trials at a single assessment. Higher score is better performance. Higher change from baseline means better performance.</description>
          <units>Score on Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.684"/>
                    <measurement group_id="O2" value="0.82" spread="0.648"/>
                    <measurement group_id="O3" value="0.03" spread="0.660"/>
                    <measurement group_id="O4" value="-0.01" spread="0.660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5950</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.860</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.18</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7057</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.865</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.40</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6741</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.865</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.36</ci_lower_limit>
            <ci_upper_limit>2.10</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - One Card Learning (OCLT).</title>
        <description>Cogstate - The One Card Learning Test (OCLT) is a measure of visual learning and uses a well-validated pattern separation paradigm with playing card stimuli. Higher Score is better performance. Higher change from baseline means better performance.</description>
        <time_frame>Baseline and Hour 3 on Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gralise® (Gabapentin)</title>
            <description>Gralise® 3 x 600 mg tablets (1800 mg total dose) administered once daily at 7:00 pm on Day 1 and Day 2 with one placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®. At other dosing times, treatment consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule.
Gabapentin</description>
          </group>
          <group group_id="O2">
            <title>Neurontin® (Gabapentin)</title>
            <description>Neurontin® 1 x 600 mg film-coated tablet administered 3 times daily at 7:00 pm on Day 1, at 8:00 am, 2:00 pm and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Neurontin® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
Gabapentin</description>
          </group>
          <group group_id="O3">
            <title>Lyrica® (Pregabalin)</title>
            <description>Lyrica® 1 x 150 mg capsule administered 2 times daily at 7:00 pm on Day 1, at 8:00 am and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Lyrica® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
Pregabalin</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Sugar Pill)</title>
            <description>Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Cognitive Evaluation of Cogstate - One Card Learning (OCLT).</title>
          <description>Cogstate - The One Card Learning Test (OCLT) is a measure of visual learning and uses a well-validated pattern separation paradigm with playing card stimuli. Higher Score is better performance. Higher change from baseline means better performance.</description>
          <units>Score on Scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.021"/>
                    <measurement group_id="O2" value="0.06" spread="0.020"/>
                    <measurement group_id="O3" value="0.00" spread="0.020"/>
                    <measurement group_id="O4" value="0.03" spread="0.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0070</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0175</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5183</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0175</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5084</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0175</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Sedation Evaluation - Karolinska Sleepiness Scale (KSS).</title>
        <description>Scale: 1-9, 1=extremely alert, 9 = very sleepy, great effort to keep awake, fighting sleep</description>
        <time_frame>Baseline and Hour 3 on Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gralise® (Gabapentin)</title>
            <description>Gralise® 3 x 600 mg tablets (1800 mg total dose) administered once daily at 7:00 pm on Day 1 and Day 2 with one placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®. At other dosing times, treatment consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule.
Gabapentin</description>
          </group>
          <group group_id="O2">
            <title>Neurontin® (Gabapentin)</title>
            <description>Neurontin® 1 x 600 mg film-coated tablet administered 3 times daily at 7:00 pm on Day 1, at 8:00 am, 2:00 pm and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Neurontin® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
Gabapentin</description>
          </group>
          <group group_id="O3">
            <title>Lyrica® (Pregabalin)</title>
            <description>Lyrica® 1 x 150 mg capsule administered 2 times daily at 7:00 pm on Day 1, at 8:00 am and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Lyrica® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
Pregabalin</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Sugar Pill)</title>
            <description>Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Sedation Evaluation - Karolinska Sleepiness Scale (KSS).</title>
          <description>Scale: 1-9, 1=extremely alert, 9 = very sleepy, great effort to keep awake, fighting sleep</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".774" spread=".2985"/>
                    <measurement group_id="O2" value=".264" spread=".2876"/>
                    <measurement group_id="O3" value=".868" spread=".2913"/>
                    <measurement group_id="O4" value=".264" spread=".2914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1026</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.510</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.307</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.104</ci_lower_limit>
            <ci_upper_limit>1.124</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7634</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.094</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.309</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.711</ci_lower_limit>
            <ci_upper_limit>0.523</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1041</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.510</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.309</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.107</ci_lower_limit>
            <ci_upper_limit>1.127</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Sedation Evaluation - Portland Neurotoxicity Scale (PNS).</title>
        <description>Portland Neurotoxicity Scale (PNS) comprises 15 questions measured on a 10-point scale. [1=No problem, 2, 3, 4, 5=Often a problem, 6, 7, 8, 9, 10=Severe problem] in 16 categories. Each question was analyzed and is presented in the same way as the primary endpoints.</description>
        <time_frame>Baseline and Hour 3 on Day 3</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Gralise® (Gabapentin)</title>
            <description>Gralise® 3 x 600 mg tablets (1800 mg total dose) administered once daily at 7:00 pm on Day 1 and Day 2 with one placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®. At other dosing times, treatment consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule.
Gabapentin</description>
          </group>
          <group group_id="O2">
            <title>Neurontin® (Gabapentin)</title>
            <description>Neurontin® 1 x 600 mg film-coated tablet administered 3 times daily at 7:00 pm on Day 1, at 8:00 am, 2:00 pm and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Neurontin® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
Gabapentin</description>
          </group>
          <group group_id="O3">
            <title>Lyrica® (Pregabalin)</title>
            <description>Lyrica® 1 x 150 mg capsule administered 2 times daily at 7:00 pm on Day 1, at 8:00 am and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Lyrica® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
Pregabalin</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Sugar Pill)</title>
            <description>Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®.
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Between, Gralise® and Neurontin®, Gralise® and Lyrica® for Sedation Evaluation - Portland Neurotoxicity Scale (PNS).</title>
          <description>Portland Neurotoxicity Scale (PNS) comprises 15 questions measured on a 10-point scale. [1=No problem, 2, 3, 4, 5=Often a problem, 6, 7, 8, 9, 10=Severe problem] in 16 categories. Each question was analyzed and is presented in the same way as the primary endpoints.</description>
          <population>Full Analysis Set</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vision (blurring, double vision)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036" spread="0.1274"/>
                    <measurement group_id="O2" value="0.322" spread="0.1235"/>
                    <measurement group_id="O3" value="0.249" spread="0.1249"/>
                    <measurement group_id="O4" value="0.115" spread="0.1249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Energy Level (get up and go)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.099" spread="0.1811"/>
                    <measurement group_id="O2" value="0.256" spread="0.1743"/>
                    <measurement group_id="O3" value="0.315" spread="0.1766"/>
                    <measurement group_id="O4" value="0.331" spread="0.1766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Memory (ability to remember people, places, or thi</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.077" spread="0.1498"/>
                    <measurement group_id="O2" value="0.123" spread="0.1441"/>
                    <measurement group_id="O3" value="0.125" spread="0.1460"/>
                    <measurement group_id="O4" value="-0.041" spread="0.1460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Walking (balance)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.206" spread="0.1245"/>
                    <measurement group_id="O2" value="0.327" spread="0.1187"/>
                    <measurement group_id="O3" value="0.405" spread="0.1206"/>
                    <measurement group_id="O4" value="0.107" spread="0.1206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interest (in activities)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.046" spread="0.1174"/>
                    <measurement group_id="O2" value="0.030" spread="0.1130"/>
                    <measurement group_id="O3" value="0.096" spread="0.1145"/>
                    <measurement group_id="O4" value="0.070" spread="0.1145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coordination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.180" spread="0.1338"/>
                    <measurement group_id="O2" value="0.392" spread="0.1289"/>
                    <measurement group_id="O3" value="0.350" spread="0.1306"/>
                    <measurement group_id="O4" value="0.218" spread="0.1306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tremor (shakiness)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.103" spread="0.0571"/>
                    <measurement group_id="O2" value="0.037" spread="0.0555"/>
                    <measurement group_id="O3" value="-0.031" spread="0.0556"/>
                    <measurement group_id="O4" value="0.068" spread="0.0556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concentration (ability to concentrate on a task)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.080" spread="0.1205"/>
                    <measurement group_id="O2" value="0.164" spread="0.1148"/>
                    <measurement group_id="O3" value="0.137" spread="0.1166"/>
                    <measurement group_id="O4" value="0.182" spread="0.1166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Speech (slurring words)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.035" spread="0.0516"/>
                    <measurement group_id="O2" value="0.133" spread="0.0493"/>
                    <measurement group_id="O3" value="0.065" spread="0.0501"/>
                    <measurement group_id="O4" value="0.103" spread="0.0501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Forgetfulness</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.118" spread="0.1128"/>
                    <measurement group_id="O2" value="0.227" spread="0.1083"/>
                    <measurement group_id="O3" value="0.175" spread="0.1098"/>
                    <measurement group_id="O4" value="0.079" spread="0.1099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness (fatigue, sedation, tiredness)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.693" spread="0.2928"/>
                    <measurement group_id="O2" value="0.635" spread="0.2802"/>
                    <measurement group_id="O3" value="1.176" spread="0.2843"/>
                    <measurement group_id="O4" value="0.541" spread="0.2844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moodiness</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.181" spread="0.1174"/>
                    <measurement group_id="O2" value="0.163" spread="0.1144"/>
                    <measurement group_id="O3" value="0.098" spread="0.1155"/>
                    <measurement group_id="O4" value="0.100" spread="0.1155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alertness</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.297" spread="0.1854"/>
                    <measurement group_id="O2" value="0.451" spread="0.1786"/>
                    <measurement group_id="O3" value="0.607" spread="0.1809"/>
                    <measurement group_id="O4" value="0.353" spread="0.1809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Attention Span</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020" spread="0.1115"/>
                    <measurement group_id="O2" value="0.133" spread="0.1070"/>
                    <measurement group_id="O3" value="0.146" spread="0.1085"/>
                    <measurement group_id="O4" value="0.015" spread="0.1085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Motivation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.185" spread="0.1338"/>
                    <measurement group_id="O2" value="0.232" spread="0.1294"/>
                    <measurement group_id="O3" value="0.368" spread="0.1309"/>
                    <measurement group_id="O4" value="0.271" spread="0.1309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vision</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0177</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.286</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.521</ci_lower_limit>
            <ci_upper_limit>-0.051</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Energy Level</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4120</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.157</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.536</ci_lower_limit>
            <ci_upper_limit>0.222</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Memory</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7724</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.046</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.362</ci_lower_limit>
            <ci_upper_limit>0.270</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Walking Balance</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4255</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.121</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.423</ci_lower_limit>
            <ci_upper_limit>0.180</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Interest in activities</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8925</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.017</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.229</ci_lower_limit>
            <ci_upper_limit>0.262</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Coordination</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1293</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.212</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.487</ci_lower_limit>
            <ci_upper_limit>0.063</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tremor</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0304</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.140</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.266</ci_lower_limit>
            <ci_upper_limit>-0.014</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Concentration</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5811</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.084</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.384</ci_lower_limit>
            <ci_upper_limit>0.217</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Speech</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1144</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.098</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.220</ci_lower_limit>
            <ci_upper_limit>0.024</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Forgetfulness</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3774</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.109</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.352</ci_lower_limit>
            <ci_upper_limit>0.135</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sleepiness</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8658</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.057</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.613</ci_lower_limit>
            <ci_upper_limit>0.727</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Moodiness</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8543</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.018</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.179</ci_lower_limit>
            <ci_upper_limit>0.216</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Alertness</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4294</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.153</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.537</ci_lower_limit>
            <ci_upper_limit>0.231</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Attention Span</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3613</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.113</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.357</ci_lower_limit>
            <ci_upper_limit>0.132</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Motivation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7201</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.047</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.305</ci_lower_limit>
            <ci_upper_limit>0.212</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vision</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0767</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.213</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.448</ci_lower_limit>
            <ci_upper_limit>0.023</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Energy Level</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2618</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.216</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.597</ci_lower_limit>
            <ci_upper_limit>0.165</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Memory</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7633</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.366</ci_lower_limit>
            <ci_upper_limit>0.269</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Walking Balance</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1968</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.198</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.502</ci_lower_limit>
            <ci_upper_limit>0.105</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Interest in Activities</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6891</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.050</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.296</ci_lower_limit>
            <ci_upper_limit>0.197</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Coordination</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2229</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.171</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.447</ci_lower_limit>
            <ci_upper_limit>0.106</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tremor</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2591</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.072</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.197</ci_lower_limit>
            <ci_upper_limit>0.054</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Concentration</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7099</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.057</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.359</ci_lower_limit>
            <ci_upper_limit>0.246</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Speech</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6215</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.031</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.154</ci_lower_limit>
            <ci_upper_limit>0.092</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Forgetfulness</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6422</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.057</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.302</ci_lower_limit>
            <ci_upper_limit>0.187</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sleepiness</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1574</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.483</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.157</ci_lower_limit>
            <ci_upper_limit>0.190</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Moodiness</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4039</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.084</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.115</ci_lower_limit>
            <ci_upper_limit>0.282</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Alertness</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1145</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.309</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.695</ci_lower_limit>
            <ci_upper_limit>0.076</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Attention Span</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3083</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.127</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.372</ci_lower_limit>
            <ci_upper_limit>0.119</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Motivation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1638</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.183</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.443</ci_lower_limit>
            <ci_upper_limit>0.0776</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Vision</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5101</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.078</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.314</ci_lower_limit>
            <ci_upper_limit>0.157</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Energy Level</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2285</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.233</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.614</ci_lower_limit>
            <ci_upper_limit>0.149</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Memory</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4612</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.200</ci_lower_limit>
            <ci_upper_limit>0.436</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Walking Balance</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5190</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.099</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.205</ci_lower_limit>
            <ci_upper_limit>0.402</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Interest in Activities</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8479</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.024</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.271</ci_lower_limit>
            <ci_upper_limit>0.223</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Coordination</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7808</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.039</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.14</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.316</ci_lower_limit>
            <ci_upper_limit>0.238</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Tremor</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0083</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.171</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.296</ci_lower_limit>
            <ci_upper_limit>-0.045</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Concentration</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5068</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.101</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.404</ci_lower_limit>
            <ci_upper_limit>0.201</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Speech</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2725</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.068</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.06</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.191</ci_lower_limit>
            <ci_upper_limit>0.055</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Forgetfulness</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7498</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.039</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.206</ci_lower_limit>
            <ci_upper_limit>0.284</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Sleepiness</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6554</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.152</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.522</ci_lower_limit>
            <ci_upper_limit>0.826</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Moodiness</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4143</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.082</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.10</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.116</ci_lower_limit>
            <ci_upper_limit>0.280</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Alertness</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7761</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.055</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.441</ci_lower_limit>
            <ci_upper_limit>0.330</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Attention Span</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9697</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.005</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.241</ci_lower_limit>
            <ci_upper_limit>0.251</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Motivation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5118</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.086</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.346</ci_lower_limit>
            <ci_upper_limit>0.174</ci_upper_limit>
            <other_analysis_desc>SE of difference estimated by dividing width of 95% CI by 4.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Between Gralise® and Neurontin® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS).</title>
        <description>Miles per Hour (mph)</description>
        <time_frame>Baseline and Hour 3 on Day 3</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Gralise® (Gabapentin)</title>
            <description>Gralise® (gabapentin) 3 x 600 mg tablets (1800 mg total): Dosed once daily in the evening on Day 1 and Day 2.</description>
          </group>
          <group group_id="O2">
            <title>Neurontin® (Gabapentin)</title>
            <description>Neurontin® (gabapentin) 1 x 600 mg film-coated tablet: Dosed 3 times daily starting in the evening on Day 1, in the morning, afternoon, and evening on Day 2, and in the morning on Day 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®: Dosed 3 times daily starting in the evening on Day 1, in the morning, afternoon, and evening on Day 2, and in the morning on Day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Between Gralise® and Neurontin® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS).</title>
          <description>Miles per Hour (mph)</description>
          <population>Full Analysis Set</population>
          <units>mph</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.831" spread="0.4844"/>
                    <measurement group_id="O2" value="0.947" spread="0.4648"/>
                    <measurement group_id="O3" value="0.851" spread="0.4715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8293</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.116</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.178</ci_lower_limit>
            <ci_upper_limit>0.947</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9705</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.020</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.089</ci_lower_limit>
            <ci_upper_limit>1.049</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Between Gralise® and Lyrica® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS).</title>
        <description>Miles per Hour (mph)</description>
        <time_frame>Baseline and Hour 3 on Day 3</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Gralise® (Gabapentin)</title>
            <description>Gralise® (gabapentin) 3 x 600 mg tablets (1800 mg total): Dosed once daily in the evening on Day 1 and Day 2.</description>
          </group>
          <group group_id="O2">
            <title>Lyrica® (Pregabalin)</title>
            <description>Lyrica® (pregabalin) 1 x 150 mg capsule: Dosed 2 times daily starting in the evening on Day 1, in the morning and evening on Day 2, and in the morning on Day 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®: Dosed 3 times daily starting in the evening on Day 1, in the morning, afternoon, and evening on Day 2, and in the morning on Day 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Between Gralise® and Lyrica® in the Driving Simulator - Standard Deviation of Vehicle Speed (SDVS).</title>
          <description>Miles per Hour (mph)</description>
          <population>Full Analysis Set</population>
          <units>mph</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.831" spread="0.4844"/>
                    <measurement group_id="O2" value="1.319" spread="0.4713"/>
                    <measurement group_id="O3" value="0.851" spread="0.4715"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3666</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.488</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.556</ci_lower_limit>
            <ci_upper_limit>0.581</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9705</p_value>
            <method>ANOVA</method>
            <method_desc>Mixed model including terms for sequence, study treatment, and period as fixed effects and subject nested within sequence as a random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.020</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.53</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.089</ci_lower_limit>
            <ci_upper_limit>1.049</ci_upper_limit>
            <estimate_desc>SE of difference estimated by dividing width of 95% CI by 4.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare the Relative Safety and Tolerability of Gralise®, Neurontin®, and Lyrica®.</title>
        <description>Number of subjects with Treatment-Emergent Adverse Events (TEAE)
Number of subjects with Serious Adverse Event (SAE)
Number of subjects discontinued due to Adverse Event (AE)</description>
        <time_frame>Screening to 1 week after Period 4 discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gralise® (Gabapentin)</title>
            <description>Gralise® (gabapentin) 3 x 600 mg tablets (1800 mg total): Dosed once daily in the evening on Day 1 and Day 2.</description>
          </group>
          <group group_id="O2">
            <title>Neurontin® (Gabapentin)</title>
            <description>Neurontin® (gabapentin) 1 x 600 mg film-coated tablet: Dosed 3 times daily starting in the evening on Day 1, in the morning, afternoon, and evening on Day 2, and in the morning on Day 3.</description>
          </group>
          <group group_id="O3">
            <title>Lyrica® (Pregabalin)</title>
            <description>Lyrica® (pregabalin) 1 x 150 mg capsule: Dosed 2 times daily starting in the evening on Day 1, in the morning and evening on Day 2, and in the morning on Day 3.</description>
          </group>
          <group group_id="O4">
            <title>Placebo (Sugar Pill)</title>
            <description>Placebo (sugar pill): Three (3) placebo tablets matching the appearance of Gralise® &amp; 1 placebo capsule matching the over-encapsulation of doses of Neurontin® &amp; Lyrica®.</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare the Relative Safety and Tolerability of Gralise®, Neurontin®, and Lyrica®.</title>
          <description>Number of subjects with Treatment-Emergent Adverse Events (TEAE)
Number of subjects with Serious Adverse Event (SAE)
Number of subjects discontinued due to Adverse Event (AE)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects Discontinued due to AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 weeks</time_frame>
      <desc>Adverse Events were reported from the signed informed consent to 30 days after the last dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Gralise® (Gabapentin)</title>
          <description>Gralise® (gabapentin) 3 x 600 mg tablets (1800 mg total): Dosed once daily in the evening on Day 1 and Day 2.</description>
        </group>
        <group group_id="E2">
          <title>Neurontin® (Gabapentin)</title>
          <description>Neurontin® (gabapentin) 1 x 600 mg film-coated tablet: Dosed 3 times daily starting in the evening on Day 1, in the morning, afternoon, and evening on Day 2, and in the morning on Day 3.</description>
        </group>
        <group group_id="E3">
          <title>Lyrica® (Pregabalin)</title>
          <description>Lyrica® (pregabalin) 1 x 150 mg capsule: Dosed 2 times daily starting in the evening on Day 1, in the morning and evening on Day 2, and in the morning on Day 3.</description>
        </group>
        <group group_id="E4">
          <title>Placebo (Sugar Pill)</title>
          <description>Placebo (sugar pill): Three (3) placebo tablets matching the appearance of Gralise® &amp; 1 placebo capsule matching the over-encapsulation of doses of Neurontin® &amp; Lyrica®.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI agrees that sponsor shall have the right to the first publication of the study results which is intended to be a joint, multi-center publication. Following the first publication, the PI may publish study data or results, provided however PI submits the proposed publication to sponsor for review at least 60 days prior to the date of the proposed publication. Sponsor may remove any information that is considered confidential and / or proprietary other than study data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Operations</name_or_title>
      <organization>Depomed</organization>
      <phone>510-744-8000</phone>
      <email>clinicaltrials@depomed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

